

**INTERNATIONAL COLLABORATION TO CONDUCT RDC/TMD-BASED RESEARCH  
IADR ANNUAL MEETING, GÖTEBORG, SWEDEN**

**MIINUTES OF MEETING**

JUNE 25, 2003

<b>Agenda</b>	<b>Action</b>
<p><b>1. Welcome: Sam Dworkin</b></p> <ul style="list-style-type: none"> <li>• Dr Dworkin welcomed all members and guests to the meeting. Names of individuals attending the meeting and their institutional affiliations are attached.</li> <li>• An overview of the “state of the consortium” including planning phase goals and objectives was given.</li> <li>• Attendees were also introduced to a new web-based textbook on the “conduct of clinical trials” sponsored by the NIH. The latter is available at the following web site – <a href="http://symptomresearch.nih.gov">http://symptomresearch.nih.gov</a>.</li> </ul>	
<p><b>2. Summary of consortium-supported activities</b></p> <p>A. Training, calibration, reliability of RDC/TMD clinical examiners: Kimberly Huggins &amp; Mike John</p> <ul style="list-style-type: none"> <li>• A review of the international reliability exercise was given by Ms Huggins. Countries trained and calibrated as part of the NIH planning grant (PI – Dr. Dworkin) included Australia, Singapore, Finland, Sweden, Denmark, Holland, Germany, Switzerland, Italy and Chile.</li> <li>• Three sites (Portland, Hawaii and San Francisco) were trained and calibrated as part of other grants.</li> <li>• RDC/TMD instructions and protocols were generally clear and easy to follow.</li> <li>• Reliability testing results from 10 centers were presented by Mike John.</li> <li>• Reliability of the RDC/TMD was generally good.</li> </ul> <p>B. Translations of the RDC/TMD from English: Richard Ohrbach</p> <ul style="list-style-type: none"> <li>• Translations completed in the past year included Italian, Korean, Spanish and Japanese.</li> <li>• Translations in progress included Arabic and Farsi.</li> <li>• Translation protocols were presented and were as follows: (a) Translation to new language, (b) back-translation to English, (c) Independent review of back-translated version, (d) commentary regarding discrepancies, (e) commentary review and response by translators, (f) review of additional translation and back translation, (g) revise commentary regarding discrepancies and (h) commentary review and response by translators.</li> <li>• Other translations completed, either in whole or in part, include Dutch, Finnish, French, German, Hebrew, Swedish, Chinese and Malay but not all have followed the translation protocol highlighted above.</li> <li>• Problems encountered included (a) omissions, (b) additions, (c) literal translations of US-based education, race/culture and household income, (e) modification of rating scales and (f) differing opinions regarding language use.</li> </ul>	

<p>C. Electronic RDC/TMD clinical and research data collection: Adrian Yap</p> <ul style="list-style-type: none"> <li>• The past, present and future of e-RDC/TMD was presented.</li> <li>• E-RDC/TMD is available in both standalone and web-based versions.</li> <li>• Results of the e-RDC/TMD trial program conducted in 2002 were presented.</li> <li>• A new NUS grant targeted at developing the next generation of computerized clinical support system has been submitted. The latter will address the lack of the current system including the need for Multilanguage support; facilities for generation of additional data capture fields etc.</li> <li>• Consortium members who are interested could try out the E-RDC/TMD system by downloading it from the following web-site: <a href="http://denet.nus.edu.sg/tmd">http://denet.nus.edu.sg/tmd</a>. The downloaded software will be valid till 31 Dec 2003.</li> </ul> <p>D. Research planning and current status: Thomas List</p> <ul style="list-style-type: none"> <li>• Projects submitted to the international consortium were presented.</li> <li>• Attendees were encouraged to contact the PI of the various projects if they are interested.</li> </ul>	
<p><b>3. Installation of new of officers and welcoming remarks</b></p> <ul style="list-style-type: none"> <li>• The following new officers were installed:  Director: Richard Ohrbach  Associate Director: Thomas List  Secretary: Adrian Yap  Treasurer: Mark Drangsholt  Program Chair: Mike John  Executive Manager Kimberly Huggins</li> <li>• The significant contribution of Dr. Dworkin in establishing the RDC/TMD and international consortium was acknowledged.</li> </ul>	
<p><b>4. Planning for the future: Group discussion</b></p> <ul style="list-style-type: none"> <li>• Dr. Ohrbach highlighted the challenges facing the consortium. These include: (a) small scale clinical studies, (b) site infrastructure development, (c) member participation (consortium committees etc), (d) transparent data collection methods, (e) large scale funded projects and (f) common goals.</li> <li>• Funding concern was also highlighted. This is needed for (a) remuneration for the executive manager, (b) requests from other centers for training and calibration, (c) annual meeting facilities and (d) web-site maintenance.</li> <li>• Recruitment for the various committees will be done through electronic form submission.</li> <li>• The need for further validity studies was highlighted following discussion regarding (a) absence of full validity for the Axis I diagnoses currently included in the RDC/TMD, and (b) absence of operationalization for the more rare TMDs. The status of the US-based RDC validation study was briefly summarized, and discussion revealed that a number of other centers are already working on other Axis I validation issues. The proposed study by Ohrbach and List would begin to address validation issues for Axis II. Consequently, the members agreed that the primary goal, at present, for the Consortium</li> </ul>	

is to focus on validation studies. <ul style="list-style-type: none"><li>• Consortium members were encouraged to capitalize on the international cross-cultural aspect of the consortium.</li></ul>	

27 June 2003

Minutes recorded by Dr. Adrian Yap.

Vetted by members of the steering committee.